CoChat

A layered cancer-on-a-chip system for anticancer drug screening and disease modeling

Open access

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; none of the 42 sources its claims cite is checked for support yet.

Abstract

conditions and more reliable response to the tested drugs. This report presents a new approach to modeling skin cancer (melanoma-on-a-chip) and breast cancer (breast cancer-on-a-chip) using the microfluidic systems. We designed a microfluidic device to co-culture cancer cells with non-malignant cells, which are the main component of the cancer microenvironment. In the construction of the microsystem, we used a scaffold in the form of a porous membrane made of poly(ethylene terephthalate), which enables the regular and reproducible arrangement of cells in the culture and maintains intercellular communication. To demonstrate the functionality of the microsystem, we used it to analyze the effectiveness of photodynamic therapy in the treatment of melanoma and chemotherapy in the treatment of breast cancer. The developed microsystem can be successfully used to model cancer diseases, especially with a layered arrangement of cells in the cancerous tissue, such as melanoma, ductal breast cancer, or breast cancer metastases to the skin.

Overview

CoChat Summary

TL;DR

The paper reports a layered cancer-on-a-chip microfluidic device that co-cultures non-malignant and cancer cells on opposite sides of porous PET membranes to model melanoma and breast cancer. It demonstrates 4-day culture and uses the models to test TPP-based photodynamic therapy and doxorubicin chemotherapy.

Key findings

  • The PDMS microsystem with six porous PET membranes supported regular, reproducible double-monolayer co-culture; in representative areas the fibroblast-to-cancer cell ratio was 1:3, and cells formed a 3D layered structure on both membrane surfaces.
  • Layered cultures were maintained for at least 4 days; mean cell number increased about 6-fold by day 4 for skin co-culture and more than 6-fold for breast co-culture, though gravity caused cancer cell detachment after 72 h and MCF-7 shape factor and sphericity each increased by 0.51 over two days.
  • TPP was non-cytotoxic in the dark from 0–5 µM; after irradiation, viability fell to 44.63 ± 22.57%, 50.89 ± 28.68%, and 29.92 ± 17.94% of control at 1, 3, and 5 µM TPP, respectively.
  • Doxorubicin reduced breast co-culture viability to 71.6 ± 22.4% at 0.1 µM, 30.7 ± 2.1% at 10 µM, and 23.9 ± 3.1% at 100 µM; because DOX was introduced through the upper layer, this indicated penetration through fibroblasts and PET pores to cancer cells.

Methods

  • Fabrication and culture: two PDMS layers with six porous PET membranes (0.4 µm pores, 2 × 10⁶ pores/cm²); non-malignant cells seeded in upper chambers at 10⁶ cells/mL and 10 µL/min, incubated 24 h, then the device was rotated 180° and cancer cells seeded in lower chambers similarly.
  • Models and assays: HaCaT keratinocytes + MeWo cells for melanoma-on-a-chip; HMF fibroblasts + MCF-7 cells for breast cancer-on-a-chip. Viability was measured by AlamarBlue and CAM/PI staining; morphology/sphericity used CellTracker dyes, confocal microscopy, and CellSens software.
  • Drug testing and statistics: DOX at 0–100 µM and TPP at 0–15 µM; PDT used LED irradiation (10 min, λ = 640 nm, 40 mW/cm²). Results are mean ± SD from 3 independent experiments with three repetitions, or three independent measurements, analyzed by one-way ANOVA at α = 0.05.

Limitations

  • The paper states that further work is needed to add a blood vessel network and immune cells to better reflect the tumor microenvironment.
  • Evident from the text: viability in co-culture was assessed without distinguishing non-malignant from cancer cells; only two cancer models/cell-line pairs were tested; gravity caused cancer cell detachment after 72 h; and PDT results showed large standard deviations.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1039/d3an00959a

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

0 Valid · 0 Not valid · 33 Not checked · 62 Own results and interpretations

43 more claims

Create a free account to see all 95 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 33
  • Probably not a substantial claim. 27

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 46 references

Research works printed but not linked: 3

  1. Yang, 2022, Cancer Biol. Med., 19, 319
  2. Pasman, 2018, J. R. Soc., Interface, 15, 20180351, 10.1098/rsif.2018.0351 · DOI · Paper page
  3. Lee, 2017, Biomed. Microdevices, 19, 1

Cited by

Metadata

Authors
Flont, M., Dybko, A., & Jastrzębska, E.
Affiliations
Warsaw University of Technology (PL)
Corresponding author
Jastrzębska, Elżbieta
Venue
The Analyst
Published
2023
Volume
148
Issue
21
Pages
5486-5495
ISSN
  • 0003-2654 (ISSN-L)
  • 1364-5528
OpenAlex
W4387008785
Cited by
21
References
46
Citations by year
2026: 3 · 2025: 9 · 2024: 9
FWCI
1.65
Type
journal article
Language
en
Open access
Locations
  • The Analyst (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Politechnika Warszawska (1820/2/Z01/POB4/2021)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Capillary Electrophoresis Applications
  • Physical Sciences › Engineering › Biomedical Engineering › Microfluidic and Bio-sensing Technologies
Keywords
microfluidics, melanoma, breast cancer, co-culture, tumor microenvironment, photodynamic therapy, chemotherapy, anticancer drug screening, disease modeling, metastasis
MeSH terms
Antineoplastic Agents, Breast Neoplasms, Drug Screening Assays, Antitumor, Female, Humans, Melanoma, Models, Biological, Photochemotherapy, Skin Neoplasms, Coculture Techniques, Cell Line, Tumor, Microfluidic Analytical Techniques, Lab-On-A-Chip Devices

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.